It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

At the start of the quarter, Carillon ClariVest Capital Appreciation Fund vs. Russell 1000 Growth Index, was most overweight ...